Our activities include sourcing and evaluation of partnering and M&A opportunities, and assistance with financings. Examples of projects include:

Spin-out from an US listed biotech
We were engaged by a private buy-out partnership to assess the opportunity for spin-out of IP assets from a US based listed biotech. This involved assessing the commercial opportunity for several large molecule therapeutic candidates. Ten projects were assessed across the therapeutic spaces of musculoskeletal and wound healing; infectious diseases; cardiovascular and metabolic disease; oncology; and anti-inflammatory diseases. We built an investment case based on commercial opportunity, therapeutic area, and how to package assets for subsequent company spin-out and financing. Members of the ATPBio team have played key roles in licensing the assets in order to establish and finance a new spin-out biotech company.

Head of Corporate Development (Interim)
We were retained by a UK biotech to identify and assess opportunities for corporate development and financing opportunities. Working closely with the CEO and investors, we opened discussions with over 50 parties (US and European biotechs and big pharma) and assessed multiple opportunities for partnering, M&A and financing. The role included developing strategic and scenario analyses, financial modelling, and active participation in raising a series B private investment round of over $10 million.

$42 million licensing transaction, gastrointestinal disease space
We performed an independent commercial and scientific review of a listed UK biotech company for a major Japanese pharma. Subsequently, the Japanese Pharma in-licensed a phase II product from the UK biotech with a headline deal value up to $42 million. The deal structure involved a $2million upfront payment, and a further $3million upon exercising rights to a licence and development agreement. A further $37 million is payable in stages on achievement of milestones. ATPBio was critical in providing an independent appraisal of the UK biotech's valuation, opportunities and risks.

$9.9million series B financing, anti-infective space
We worked on series B financing for a privately held biotech company developing novel anti-bacterial compounds. We originated the client, introduced an FSA regulated life sciences corporate finance house, and worked closely with corporate finance house on the project. ATPBio was the lead author on the investment memorandum, and formed part of the team that approached over 70 life science specialist VCs throughout UK and Europe. We also performed research on the market and competitor analysis, and explored international M&A opportunities in parallel to the financing. The company raised $9.9 million, and the financing was completed in May 2005.